Abstract:Jianxia Ma, &ast Ke Wang, &ast Jun Wang, Qinlian Zeng, Kangwei Liu, Songbai Zheng, Yuanwen Chen, Jianfeng Yao Department of Gastroenterology, Hua Dong Hospital of Fu Dan University, Shanghai, 200040, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jianfeng Yao, Department of Gastroenterology, HuaDong Hospital of Fu Dan University, No. 221. Road West Yanan, Shanghai, 200040, People's Republic of China, Tel +8602162483180, Email Objective: The fecal microbiota was studied in patients with inflammatory bowel disease (IBD), and the characteristics of gut microbiota were compared among patients with different subtypes and stages of IBD, aiming to identify the gut microbiota associated with IBD. Methods: Fecal samples were collected from 41 IBD patients (18 patients with ulcerative colitis [UC] and 23 patients with Crohn's disease [CD]) in the Department of Gastroenterology of East China Hospital, Fudan University between January 2021 and January 2022. In addition, fecal samples were collected from 20 healthy volunteers. The fecal microbiota was subjected to 16S rRNA gene sequencing, followed by bioinformatics analysis. Results: There was significant difference in the fecal microbiota between IBD patients and controls. The abundance and diversity of fecal microbiota in the IBD patients were significantly lower than in controls. The relative abundance of Subdoligranulum, Ruminococcus, Anaerostipes and Lachnospira was reduced markedly in the IBD patients. As compared to controls, the relative abundance of Streptococcus increased dramatically in the UC patients. The relative abundance of Lachnoclostridium, Fusobacterium, Cloacibacillus and Erysipelatoclostridium significantly increased in the CD patients. As compared to CD patients, the relative abundance of Alistipes was reduced markedly in the UC patients; the relative abundance of Faecalibacterium, Roseburia and Haemophilus was reduced dramatically in the CD patients. In addition, significant difference was also noted in the fecal microflora between patients with active IBD and those with IBD in remission period. In active IBD patients, the relative abundance of Roseburia, Coprococcus and Ruminiclostridium was reduced significantly. Conclusion: There is intestinal microbiota imbalance in IBD patients, and the abundance of Roseburia, Coprococcus and Ruminiclostridium is reduced significantly in the active period of IBD, which may be related to the active IBD. Keywords: inflammatory bowel disease, ulcerative colitis, Crohn's disease, gut microbiota, 16S rRNA gene sequencing Inflammatory bowel disease (IBD) is a chronic, relapsing intestinal inflammatory disease and can be divided into ulcerative colitis (UC) and Crohn's disease (CD). Environment, genetic susceptibility, abnormal immune response of the intestinal mucosa, and gut microbiota are involved in the occurrence and development of IBD. In recent years, increasing evidence has shown that intestinal microbiota disorder is closely related to the pathogenesis of IBD. 1 The global incidence of IBD is increasing over year, and the annual incidence of IBD varies from 0.1/100000 to 58/100000 in different regions. 2 The incidence of CD is 6.3/100000–23.8/100000 each year in North America, but it is about 54/100000 3,4 each year in the Asia Pacific region, and the incidence of IBD is closely related to the regions and socio-economic development. With the rapid economic development in Asia Pacific region (especially China) and the change of lifestyle, such as the industrialization, urbanization, air pollution, popularization of western diet (high calorie diet), the incidence of IBD is growing rapidly, but the incidence of IBD has become relatively stable in the industrialized regions such as Europe. A meta-analysis 5 investigated 48 studies, in which there were 2221 IBD patients (1206 CD patients and 1015 UC patients) and 2063 healthy controls. Among them, 34 studies investigated the microbiota of CD patients, and 29 studies examined the microbiota of UC. All 3 studies of Christensenellaceae and Coriobacteriaceae and 6 of 11 studies of Faecalibacterium prausnitzii reported a decreased amount of those organisms compared with controls, whereas 2 studies each of Actinomyces, Veillonella, and Escherichia coli revealed an increased amount in patients with Crohn's disease. For patients with ulcerative colitis, Eubacterium rectale and Akkermansia were decreased in all 3 studies, whereas E coli was increased in 4 of 9 studies. The microbiota diversity was either decreased or not different in patients with IBD -Abstract Truncated-

P1219 Changes in gut microbiota of patients with inflammatory bowel disease receiving biologic therapy

Alternations of the gut microbiota and the Firmicutes/Bacteroidetes ratio after biologic treatment in inflammatory bowel disease

Deciphering Microbial Composition in Patients with Inflammatory Bowel Disease: Implications for Therapeutic Response to Biologic Agents

Biologic Therapy for Crohn's Disease over the Last 3 Decades.

Increased Proportions of Bifidobacterium and the Lactobacillus Group and Loss of Butyrate-Producing Bacteria in Inflammatory Bowel Disease

P1232 Alterations in microbial composition in patients with newly diagnosed Crohn's disease over a course of one year: data from a prospective longitudinal real-world study

P010 Faecal microbiota composition by shotgun metagenomic sequencing approach in a newly diagnosed cohort of inflammatory bowel disease patients: results from the IBDomics project

Microbial Disruptions in Inflammatory Bowel Disease: A Comparative Analysis

P060 Increased metabolic activity of faecal Sutterella Wadsworthensis at IBD onset is associated with an increased risk of escalation to biologic therapies - Results from the Birimingham Inception Cohort Study

Dysbiosis and Associated Stool Features Improve Prediction of Response to Biological Therapy in Inflammatory Bowel Disease

Gut microbiota and metabolites as predictors of biologics response in inflammatory bowel disease: A comprehensive systematic review

P1241 Distinct gut microbiota in Crohn's Disease between inflammatory B1 and stricturing B2 phenotype

Colonic microbiota is associated with inflammation and host epigenomic alterations in inflammatory bowel disease

Characteristics of Fecal and Mucosa-Associated Microbiota in Chinese Patients With Inflammatory Bowel Disease

P1230 Integrated analysis of microbiome and metabolome reveals disease-specific profiles in inflammatory bowel disease and intestinal Behcet’s disease

P1149 Risk of Clostridioides difficile infection in patients with inflammatory bowel disease

Gut microbiome structure and metabolic activity in inflammatory bowel disease

P842 Analysis of fungal microbiota dysbiosis in inflammatory bowel disease

Influence of Crohn's disease related polymorphisms in innate immune function on ileal microbiome

Gut microbiome and mycobiome in inflammatory bowel disease patients with Clostridioides difficile infection

Increased abundance of proteobacteria in aggressive Crohn’s disease seven years after diagnosis